375 related articles for article (PubMed ID: 27761077)
41. Antibacterial and Anti-Biofilm Activity of Omega-3 Polyunsaturated Fatty Acids against Periprosthetic Joint Infections-Isolated Multi-Drug Resistant Strains.
Coraça-Huber DC; Steixner S; Wurm A; Nogler M
Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33810261
[No Abstract] [Full Text] [Related]
42. Synergistic effect of artocarpin on antibacterial activity of some antibiotics against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli.
Septama AW; Panichayupakaranant P
Pharm Biol; 2016; 54(4):686-91. PubMed ID: 26427318
[TBL] [Abstract][Full Text] [Related]
43. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
Fritsche TR; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
[TBL] [Abstract][Full Text] [Related]
44. Antimicrobial Resistance Profile of Planktonic and Biofilm Cells of Staphylococcus aureus and Coagulase-Negative Staphylococci.
de Oliveira A; Cataneli Pereira V; Pinheiro L; Moraes Riboli DF; Benini Martins K; Ribeiro de Souza da Cunha Mde L
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598130
[TBL] [Abstract][Full Text] [Related]
45. In vitro antibacterial activity of ceftobiprole against clinical isolates from French teaching hospitals: proposition of zone diameter breakpoints.
Lascols C; Legrand P; Mérens A; Leclercq R; Muller-Serieys C; Drugeon HB; Kitzis MD; Reverdy ME; Roussel-Delvallez M; Moubareck C; Brémont S; Miara A; Gjoklaj M; Soussy CJ
Int J Antimicrob Agents; 2011 Mar; 37(3):235-9. PubMed ID: 21295447
[TBL] [Abstract][Full Text] [Related]
46. In vitro activity of fusidic acid and mupirocin against coagulase-positive staphylococci from pets.
Loeffler A; Baines SJ; Toleman MS; Felmingham D; Milsom SK; Edwards EA; Lloyd DH
J Antimicrob Chemother; 2008 Dec; 62(6):1301-4. PubMed ID: 18819974
[TBL] [Abstract][Full Text] [Related]
47. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011).
Jones RN; Sader HS; Flamm RK
Diagn Microbiol Infect Dis; 2013 Mar; 75(3):304-7. PubMed ID: 23357293
[TBL] [Abstract][Full Text] [Related]
48. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011.
Morrissey I; Seifert H; Canton R; Nordmann P; Stefani S; Macgowan A; Janes R; Knight D;
J Antimicrob Chemother; 2013 Jan; 68(1):164-7. PubMed ID: 22941898
[TBL] [Abstract][Full Text] [Related]
49. Genomic characterization of coagulase-negative staphylococci including methicillin-resistant Staphylococcus sciuri causing bovine mastitis.
Khazandi M; Al-Farha AA; Coombs GW; O'Dea M; Pang S; Trott DJ; Aviles RR; Hemmatzadeh F; Venter H; Ogunniyi AD; Hoare A; Abraham S; Petrovski KR
Vet Microbiol; 2018 Jun; 219():17-22. PubMed ID: 29778192
[TBL] [Abstract][Full Text] [Related]
50. Synergism of coumarins from the Chinese drug Zanthoxylum nitidum with antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA).
Zuo GY; Wang CJ; Han J; Li YQ; Wang GC
Phytomedicine; 2016 Dec; 23(14):1814-1820. PubMed ID: 27912884
[TBL] [Abstract][Full Text] [Related]
51. In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea.
Hwang SH; Kim MN; Pai CH; Huh DH; Shin WS
Yonsei Med J; 2000 Oct; 41(5):563-9. PubMed ID: 11079615
[TBL] [Abstract][Full Text] [Related]
52. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci.
Jones RN; Deshpande LM; Mutnick AH; Biedenbach DJ
J Antimicrob Chemother; 2002 Dec; 50(6):915-32. PubMed ID: 12461013
[TBL] [Abstract][Full Text] [Related]
53. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
[TBL] [Abstract][Full Text] [Related]
54. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
[TBL] [Abstract][Full Text] [Related]
55. Levonadifloxacin (WCK 771) exerts potent intracellular activity against
Dubois J; Dubois M
J Med Microbiol; 2019 Dec; 68(12):1716-1722. PubMed ID: 31689174
[No Abstract] [Full Text] [Related]
56.
Hamza M; Nadir M; Mehmood N; Farooq A
Indian J Pharmacol; 2016; 48(6):710-714. PubMed ID: 28066112
[TBL] [Abstract][Full Text] [Related]
57. High prevalence of methicillin-resistant coagulase-negative staphylococci isolated from a university environment in Thailand.
Seng R; Leungtongkam U; Thummeepak R; Chatdumrong W; Sitthisak S
Int Microbiol; 2017 Jun; 20(2):65-73. PubMed ID: 28617524
[TBL] [Abstract][Full Text] [Related]
58. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci.
Putnam SD; Sader HS; Farrell DJ; Biedenbach DJ; Castanheira M
Int J Antimicrob Agents; 2011 Jan; 37(1):39-45. PubMed ID: 21075602
[TBL] [Abstract][Full Text] [Related]
59. Antibacterial and Antibiofilm Potential of Bacterial Cellulose Hydrogel Containing Vancomycin against Multidrug-Resistant
Correia AAV; de Almeida Campos LA; de Queiroz Macêdo HLR; de Lacerda Coriolano D; Agreles MAA; Xavier DE; de Siqueira Ferraz-Carvalho R; de Andrade Aguiar JL; Cavalcanti IMF
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785836
[TBL] [Abstract][Full Text] [Related]
60. Chemical Composition Related to Antimicrobial Activity of Moroccan
Tiji S; Rokni Y; Benayad O; Laaraj N; Asehraou A; Mimouni M
Evid Based Complement Alternat Med; 2021; 2021():8308050. PubMed ID: 34725555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
